Abstract: Provided herein are methods for treatment of a neurodegenerative disease, such as neuronal ceroid lipofuscinosis including administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of an agent that mediates upregulation of TPP1.
Abstract: Methods of modulating peroxisome proliferator-activated receptor ? (PPAR?) activity in a cell in a subject in need thereof are provided. The methods include administering an effective amount of a PPAR? ligand to the subject where the PPAR? ligand is selected from 3-hydroxy-2,2-dimethyl butyrate (HMB), hexadecananamide (HEX) and 9-octadecenamide (OCT). Methods of treating dementia, neurodegenerative disorders, lysosomal storage diseases and body weight disorders in a subject in need thereof are provided. The methods include administering an effective amount of a PPAR? ligand to the subject.
Abstract: An inanimate model for surgical simulation and methods for making and using the model are provided. The model includes a simulated diaphragm, a simulated esophagus extending through an esophageal opening in the diaphragm, a simulated blood vessel extending through a blood vessel opening in the diaphragm, and a simulated hernia in the diaphragm.
Abstract: Compositions for inhibiting the binding between ACE2 and SARS-CoV-2 spike S1 are disclosed. Methods of treating COVID-19 are disclosed. Methods of making an in vivo model of COVID-19 are also disclosed.
Abstract: The present invention generally relates to leadless pacemaker devices for facilitating regulation of a patient's heart rate and to methods of implanting and using such devices. In one embodiment, the pacemaker device includes a first and a second expandable structure connected by a neck region. A pacemaker unit is contained within one of the expandable structures and a power source is contained within the other of the expandable structures and is electrically connected to the pacemaker unit.
Abstract: Methods and compositions for treating acute kidney injury in a subject are provided. The methods include measuring or having measured a level of soluble urokinase plasminogen activator receptor (suPAR) in a biological sample from the subject, determining or having determined the level of suPAR in the sample compared to a control suPAR level, and administering a therapeutically effective amount of an agent that antagonizes soluble urokinase plasminogen activator receptor (suPAR) to the subject having an elevated level of suPAR relative to the control suPAR level.
Type:
Application
Filed:
September 30, 2019
Publication date:
May 5, 2022
Applicant:
Rush University Medical Center
Inventors:
Jochen REISER, Salim HAYEK, Arshed A. QUUYUMI
Abstract: This disclosure relates to pharmaceutical compositions and formulations useful for inhibiting the progression of glycine encephalopathy. The pharmaceutical compositions and formulations may include glyceryl tribenzoate. The pharmaceutical compositions and formulations may include glyceryl dibenzoate. The pharmaceutical compositions and formulations may be orally administered to the patient.
Abstract: One aspect of the invention provides a method for treating a cancer including administering to a subject in need of such treatment a composition including a therapeutically effective amount of an antibody directed against p40 monomer or an immunologically active fragment thereof. In various embodiments, the antibody is a polyclonal, monoclonal, human, humanized, and chimeric antibody; a single chain antibody or an epitope-binding antibody fragment. In other embodiments, the cancer is, for example, prostate cancer, breast cancer or liver cancer.
Abstract: Provided herein are methods for delivering acetylsalicylic acid via nasal delivery for the treatment of neurodegenerative and lysosomal storage disorders, such as Alzheimer's disease and Batten disease.
Abstract: The present invention generally relates to methods for treating neurological and other disorders, including autoimmune disorders. One aspect of the invention relates to a method of treating a disorder in which Toll-like Receptor 2 (TLR2) activation by binding to myeloid differentiation primary response 88 (MyD88) plays a role in disease pathogenesis. In one embodiment the method includes the administration of a composition, including a peptide sequence, that inhibits the activation of TLR2 by MyD88.
Abstract: One aspect of the invention provides a method of determining metal ion levels in the patents due to corrosion and wear processes of the metallic implant in a human or veterinary patient. One embodiment provides a cost effective and patient driven early diagnostic method which has a potential application in orthopedics and dentistry. In one embodiment, the method includes the use of an electrochemical biosensor to detect metal ions or particles in a sample taken from a patient having a metallic implant.
Type:
Grant
Filed:
March 11, 2015
Date of Patent:
October 26, 2021
Assignees:
Rush University Medical Center, Board of Regents, The University of Texas System
Inventors:
Mathew T. Mathew, Shalini Prasad, Markus A. Wimmer, Nadim J. Hallab, Joshua Jacobs
Abstract: Compositions for inhibiting the binding between ACE2 and SARS-CoV-2 spike S1 are disclosed. Methods of treating COVID-19 are disclosed. Methods of making an in vivo model of COVID-19 are also disclosed.
Abstract: Methods of selecting a subject for treatment of amyotrophic lateral sclerosis (ALS) and methods of treatment for subjects having ALS or at risk of developing ALS are provided. The method of selecting subjects for treatment includes obtaining a biological sample from the subject, where the sample is obtained from the subject's gastrointestinal tract or skeletal muscle. The method further includes measuring a biomarker in the subject's sample and selecting the subject for treatment of ALS when the biomarker measurement in the subject's sample is lower or higher relative to a control measurement.
Type:
Grant
Filed:
May 11, 2015
Date of Patent:
October 12, 2021
Assignee:
Rush University Medical Center
Inventors:
Jun Sun, Jingsong Zhou, Shaoping Wu, Jianxun Yi
Abstract: The present invention generally relates to compositions and methods for stimulating astroglial uptake and degradation of amyloid-? protein aggregates. One aspect of the invention provides a method of preventing or treating Alzheimer's disease including administrating a clinically effective amount of combination of vitamin A or a derivative thereof and an agonist of proliferator-activated receptor a (“PPAR?”) to a human or veterinary subject in need of such treatment.
Abstract: Methods and compositions are provided for treating an infection and promoting wound healing. The methods include administering an immunomodulator. In some aspects, the immunomodulator may be combined with an antibiotic.
Abstract: Methods of administering apoptotic compensatory proliferation signaling vesicles (AC PS Vs), and pharmaceutical formulations thereof, are described herein. AC PS Vs can be used to promote proliferation of cells in injured or diseased tissues, for example by adding a therapeutically effective amount of APCSVs to the injured or diseased tissue.
Abstract: Methods and devices for increasing endothelialization on a surface of a medical device are provided. The methods include delivering the medical device to an intravascular site and the medical device has an ?-gal epitope attached to the surface of the medical device.
Type:
Application
Filed:
June 12, 2019
Publication date:
August 26, 2021
Applicant:
Rush University Medical Center
Inventors:
Jeffrey Scott SOBLE, Uri GALILI, Gary SCHAER
Abstract: Disclosed herein is the de novo synthesis of phosphorylated polyethylene glycol compounds with three defined ABA (hydrophilic/-phobic/-philic) structures: ABA-PEG10k-Pi10, ABA-PEG16k-Pi14, and ABA-PEG20k-Pi20 and linear polymer PEG20k-Pi20 absent of hydrophobic block. The disclosure also provides materials and methods for treating or reducing the risk or likelihood of developing, anastomotic leak or other microbe-mediated disorders by administering a therapeutically effective amount of a plasminogen inhibitor such as tranexamic acid and/or a phosphate-loaded polymer.
Type:
Application
Filed:
April 23, 2019
Publication date:
August 19, 2021
Applicants:
THE UNIVERSITY OF CHICAGO, RUSH UNIVERSITY MEDICAL CENTER
Inventors:
John C. ALVERDY, Olga Y. ZABORINA, Richard A. JACOBSON
Abstract: Methods of treating cancer in a subject and compositions are provided. The methods include administering a therapeutically effective amount of a poly (ADP ribose) polymerase (PARP) inhibitor to the subject in need thereof and administering a therapeutically effective amount of a folic acid supplement to the subject. Also described herein are methods for identifying a subject having cancer and having an elevated folate receptor expression level relative to a folate receptor expression level in a subject free of cancer and administering a therapeutically effective amount of a PARP inhibitor to the subject having the elevated folate receptor level. Also described herein are compositions including a PARP inhibitor and a folic acid supplement.
Abstract: Methods and compositions for treating sinusitis in a subject are provided. The methods include administering to the subject an effective amount of a composition that stimulates growth or activity of a genus of bacteria that is decreased relative to a control subject not having sinusitis and/or inhibiting growth or activity of a genus of bacteria that is increased relative to the control subject.